Small Cap Gainers: MOXC, RCUS, ATOS
3:05 pm Thursday, June 24th, 2021
Moxian Inc (NASDAQ:MOXC) continues its recent rally on high relative volume, now extending its gains to approx. +127% month-to-date and reaching new multi-year highs. The stock is now up by 14% to $22.87. Moxian, Inc. operates a social network platform that integrates social media and business into a single platform in China. The company’s products and services focuses on creating interaction between users and merchant clients by allowing merchant clients to study consumer behavior. It serves small and medium sized enterprises.
Arcus Biosciences Inc (NYSE:RCUS) surged 15.3% to $26.98 after the company announced that at the first interim analysis of the three-arm randomized Phase 2 ARC-7 study, both arms with domvanalimab-based combinations showed encouraging clinical activity as measured by overall response rate when given as an initial treatment treatment to people with metastatic, PD-L1 > or =50% non-small cell lung cancer. Preparations for additional Phase 3 studies are underway; partner Gilead Sciences (GILD) is expected to make a decision regarding opting into co’s anti-TIGIT program later this year.
Atossa Therapeutics Inc (NASDAQ:ATOS) sees continued strength, again reaching new three-year highs. The stock currently trades higher by approx. +151% month-to-date. The stock jumped 14.62% by afternoon session on Thursday to $8.20. First, fund managers are likely buying shares ahead of Atossa’s pending inclusion into the Russell 2000 and Russell 3000 indexes. Second, investors (especially those in the Reddit community) could be attempting to set off a gamma squeeze — buying lots of short-dated call options in a way that pressures market makers to buy more shares, causing the underlying stock price to skyrocket.
